Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.
Adult
Aged
Antiviral Agents
/ therapeutic use
Drug Therapy, Combination
Female
Humans
Hydroxychloroquine
/ therapeutic use
Immunoglobulins, Intravenous
/ therapeutic use
Immunologic Factors
/ therapeutic use
Length of Stay
Lopinavir
/ therapeutic use
Male
Middle Aged
Ritonavir
/ therapeutic use
SARS-CoV-2
Treatment Outcome
COVID-19 Drug Treatment
COVID-19
Coronavirus
IVIg
Intravenous Immunoglobulin
Pulmonary infection
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
24
09
2020
revised:
29
10
2020
accepted:
10
11
2020
pubmed:
21
11
2020
medline:
23
1
2021
entrez:
20
11
2020
Statut:
ppublish
Résumé
The newly discovered coronavirus has turned into coronavirus disease 2019 (COVID-19) pandemic and it rages at an unprecedented rate. Considering the findings of previous studies on the use of Intravenous Immunoglobulin (IVIg) for treating severe H In this randomized controlled trial, 84 patients were included: 52 in the IVIg group and 32 in the control group. The intervention group received IVIg at a dose of 400 mg/kg, IV, daily for three days. Both groups received hydroxychloroquine, lopinavir/ritonavir and supportive care. The demographic data, mortality rate, the need for mechanical ventilation, length of stay in hospital and in Intensive Care Unit (ICU), and imaging findings were recorded and compared in terms of the mentioned factors. The mean time from admission to IVIg initiation was 3.84 ± 3.35 days. There was no significant difference between the two groups in terms of mortality rate (P-value = 0.8) and the need for mechanical ventilation (P-value = 0.39). The length of hospital stay was significantly lower for the control group than that of the intervention group (P-value = 0.003). There was a significant positive relationship between the time from hospital admission to IVIg initiation and the length of stay in the hospital and ICU among the survivors (P-value < 0.001 and =0.01, respectively). Our findings did not support the use of IVIg in combination with hydroxychloroquine and lopinavir/ritonavir in treatment of severe COVID-19 cases.
Sections du résumé
BACKGROUND
BACKGROUND
The newly discovered coronavirus has turned into coronavirus disease 2019 (COVID-19) pandemic and it rages at an unprecedented rate. Considering the findings of previous studies on the use of Intravenous Immunoglobulin (IVIg) for treating severe H
METHODS
METHODS
In this randomized controlled trial, 84 patients were included: 52 in the IVIg group and 32 in the control group. The intervention group received IVIg at a dose of 400 mg/kg, IV, daily for three days. Both groups received hydroxychloroquine, lopinavir/ritonavir and supportive care. The demographic data, mortality rate, the need for mechanical ventilation, length of stay in hospital and in Intensive Care Unit (ICU), and imaging findings were recorded and compared in terms of the mentioned factors.
RESULTS
RESULTS
The mean time from admission to IVIg initiation was 3.84 ± 3.35 days. There was no significant difference between the two groups in terms of mortality rate (P-value = 0.8) and the need for mechanical ventilation (P-value = 0.39). The length of hospital stay was significantly lower for the control group than that of the intervention group (P-value = 0.003). There was a significant positive relationship between the time from hospital admission to IVIg initiation and the length of stay in the hospital and ICU among the survivors (P-value < 0.001 and =0.01, respectively).
CONCLUSIONS
CONCLUSIONS
Our findings did not support the use of IVIg in combination with hydroxychloroquine and lopinavir/ritonavir in treatment of severe COVID-19 cases.
Identifiants
pubmed: 33214093
pii: S1567-5769(20)33672-9
doi: 10.1016/j.intimp.2020.107205
pmc: PMC7665876
pii:
doi:
Substances chimiques
Antiviral Agents
0
Immunoglobulins, Intravenous
0
Immunologic Factors
0
Lopinavir
2494G1JF75
Hydroxychloroquine
4QWG6N8QKH
Ritonavir
O3J8G9O825
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
107205Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Références
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Curr Pharmacol Rep. 2020;6(3):56-70
pubmed: 32395418
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
J Infect. 2020 Aug;81(2):318-356
pubmed: 32283154
Arthritis Rheum. 2013 Oct;65(10):2713-23
pubmed: 23840006
Int J Biol Sci. 2020 Mar 15;16(10):1678-1685
pubmed: 32226285
Clin Immunol. 2020 Jul;216:108459
pubmed: 32418917
Chest. 2013 Aug;144(2):464-473
pubmed: 23450336
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102
pubmed: 32258207
J Neurol. 2008 Jul;255 Suppl 3:3-6
pubmed: 18685919